Bio-Techne Corporation, in collaboration with ScaleReady, Wilson Wolf Manufacturing, and CellReady, has announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant. This funding is part of a broader initiative aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India. The grant will support Immuneel's process development, validation, and comparability studies at their state-of-the-art GMP facility in Bengaluru. This initiative is part of ScaleReady's G-Rex Grant Program, which has increased its total award funds to $30 million. The program has already awarded 200 grants, with each recipient eligible for up to $300,000 and access to exclusive support from a consortium of G-Rex Grant Partners.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。